DCGI grants EUA to Corbevax for those aged 5-12 Covaxin for 6-12 age group
New Delhi Apr 26 PTI Indias drug regulator has granted restricted emergency use authorisation for Biological Es COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotechs Covaxin for children in the age group of six to 12 years Union Health Minister Mansukh Mandaviya said on TuesdayThe approval by the Drugs Controller General of India DCGI for Corbevax and Covaxin for inoculating children below 12 years paves the way for giving protection to a majority of school going children and assumes significance ahead of Prime Minister Narendra Modis meeting with chief ministers on the emerging COVID-19 situation in the country on Wednesday through video conferencingThe DCGI has also granted emergency use authorisation EUA to Cadila for its ZyCoV-D for an additional dose of 3mg with a two-jab inoculation schedule 28 days apart for those aged above 12 yearsZyCoV-D is currently approved for a 2mg three-dose vaccination scheduleThe DCGI approval comes following recommendations by the Subject Expert Committee SEC on COVID-19 of the Central Drugs Standard Control OrganisationCDSCOThe SEC had last week reviewed the application of Biological E and Bharat Biotech seeking emergency use authorisation for Corbevax and Covaxin for use in children of five to 12 years and six to 12 years age group respectively It also reviewed Cadilas applicationBiological Es Corbevax is being used to inoculate children against COVID-19 in the age group of 12 to 14 years Covaxin has been granted Emergency Use Listing EUL by the DCGI for the age group of 12 to 18 years on December 24 2021India began inoculating children aged 12-14 years on March 16 So far more than 270 crore adolescents have been administered with the first dose of COVID-19 vaccineThe countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase Vaccination of frontline workers started from February 2 last yearThe next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditionsIndia launched vaccination for all people aged more than 45 years from April 1 last year The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last yearThe next phase of vaccination commenced on January 3 for adolescents in the age group of 15-18 yearsIndia began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10Precaution doses of COVID-19 vaccines to all aged above 18 years were allowed at private vaccination centres from April 10 The cumulative COVID-19 vaccine doses administered in the country has exceeded 18795 crore PTI PLB SRY
New Delhi Apr 26 PTI Indias drug regulator has granted restricted emergency use authorisation for Biological Es COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotechs Covaxin for children in the age group of six to 12 years Union Health Minister Mansukh Mandaviya said on TuesdayThe approval by the Drugs Controller General of India DCGI for Corbevax and Covaxin for inoculating children below 12 years paves the way for giving protection to a majority of school going children and assumes significance ahead of Prime Minister Narendra Modis meeting with chief ministers on the emerging COVID-19 situation in the country on Wednesday through video conferencingThe DCGI has also granted emergency use authorisation EUA to Cadila for its ZyCoV-D for an additional dose of 3mg with a two-jab inoculation schedule 28 days apart for those aged above 12 yearsZyCoV-D is currently approved for a 2mg three-dose vaccination scheduleThe DCGI approval comes following recommendations by the Subject Expert Committee SEC on COVID-19 of the Central Drugs Standard Control OrganisationCDSCOThe SEC had last week reviewed the application of Biological E and Bharat Biotech seeking emergency use authorisation for Corbevax and Covaxin for use in children of five to 12 years and six to 12 years age group respectively It also reviewed Cadilas applicationBiological Es Corbevax is being used to inoculate children against COVID-19 in the age group of 12 to 14 years Covaxin has been granted Emergency Use Listing EUL by the DCGI for the age group of 12 to 18 years on December 24 2021India began inoculating children aged 12-14 years on March 16 So far more than 270 crore adolescents have been administered with the first dose of COVID-19 vaccineThe countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase Vaccination of frontline workers started from February 2 last yearThe next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditionsIndia launched vaccination for all people aged more than 45 years from April 1 last year The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last yearThe next phase of vaccination commenced on January 3 for adolescents in the age group of 15-18 yearsIndia began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10Precaution doses of COVID-19 vaccines to all aged above 18 years were allowed at private vaccination centres from April 10 The cumulative COVID-19 vaccine doses administered in the country has exceeded 18795 crore PTI PLB SRY
